← All trials
NCT06148025
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Oct 31, 2027
- Completion date
- Oct 31, 2028
- First posted
- Nov 28, 2023
- Last posted
- Nov 28, 2023
- Enrollment
- 348
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- South Australian Health and Medical Research InstituteLead sponsor
- Flinders UniversityCollaborator
- University of AdelaideCollaborator
- University of AdelaideOverall official - principal investigator
- South Australian Health and Medical Research InstituteOverall official - principal investigator
- South Australian Health and Medical Research InstituteReponsible party - principal investigator
- Telethon Kids InstituteCollaborator
- University of SydneyCollaborator
- University of AdelaideOfficial
- South Australian Health and Medical Research InstituteSponsor investigator
- South Australian Health and Medical Research InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.